These guidelines are informed by evidence of ‘what works’ and lessons learned in the field. They are designed to accelerate UNICEF regional and country offices’ programming on social service workforce strengthening, and support work to better plan, develop and support the social services workf...orce with national and regional partners.
more
Journal of Infection and Public Health 12 (2019) 213–223
The synthesis looked across the evaluations and reviews as mentioned above to draw lessons and conclusions across the different contexts. The synthesis aims to identify:
recurrent issues, patterns and trends, and promising initiatives and lessons learned from existing programming including main...streaming in how UNHCR prevents, mitigates and responds to the risks of SGBV;
institutional management and leadership for SGBV in UNHCR;
factors which are contributing to success, including sustainability of services, and those which are inhibiting it;
the extent to which questions on SGBV are part of UNHCR evaluations of emergency responses;
more
Since May 2019, Confirmation of 4 new emergence of type 2 vaccine-derived poliovirus (VDPV2) in Bambari (2) and Bimbo (2) health districts without any genetic link between them and other known viruses ; Bambari Health District: CAF-RS4-BAM-19-058, onset of paralysis: May 02, 2019. 07 positive contac...ts with the same genetic link. Community samples CAF-RS4-BAM-19-058CC14 and CAF-RS4-BAM-19-058CC17 positive, genetically related to each other but not genetically linked to the CAF-RS4-BAM-19-058 index case (new emergence)
more
Amsterdam, the Netherlands, 23 July 2018
Meeting Report
The following protocol has been designed to investigate the First Few X cases (FFX) and their close contacts. It is envisioned that the FFX 2019-nCoV investigation will be conducted across several countries or sites with geographical and demographical diversity. Using a standardized protocol such a...s the protocol provided here, epidemiological exposure data and biological samples can be systematically collected and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally for timely estimates of 2019-nCoV infection severity and transmissibility, as well as to inform public health responses and policy decisions. This is particularly important in the context of a novel respiratory pathogen, such as 2019-nCoV
more
12 April 2020
This Guidance Note on making COVID-19 response Age & Disability-inclusive provides advice for organizations and sectors to ensure essential responses, communication about the outbreak and adapt to services and support are inclusive and accessible for older persons and persons with d...isabilities.
more
Coronavirus disease 2019 is also known as COVID-19. It is a viral illness that infects the lungs. It is caused by a virus called SARS-associated coronavirus (SARS-CoV-2). This illness was first seen in late 2019 in China and has spread across the world.
The signs of COVID-19 are like the flu, and y...ou may have a cough, fever, and it may be hard to breathe. It spreads easily through droplets with the virus when you sneeze or cough. The germs also survive on surfaces like tables, door handles, and telephones. That means you can become sick if you touch a surface with the virus and then touch your face.
Some people have a mild case of COVID-19 and are able to stay at home until they feel better. Others may need to be in the hospital if they are very sick. People with COVID-19 most often have to isolate themselves for about 2 weeks.
Last Reviewed Date: 2020-03-16
more
This document offers guidance to Member States in the African region on the key steps used to conduct contact tracing related to the COVID-19 response. It is to be used by national and local health authorities in the implementation of tracing of contacts of probable and confirmed COVID-19 cases.
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This... policy brief was developed by the WHO Access to COVID-19 Tools (ACT) Accelerator Ethics & Governance Working Group, to provide guidance for researchers, sponsors, regulators, research ethics committees, and policy-makers, on these and related issues.
more
Indonesia, Malaysia, Myanmar, and Pakistan
Spetember 2020